Erratum to: ROS1 gene rearrangement and copy number gain in non-small cell lung cancer(Virchows Arch, (2015), 466, 45-52, Doi:10.1007/s00428-014-1679-2);ROS1 gene rearrangement and copy number gain in Non-Small cell lung cancer

Virchows Archiv

Volumn 466, Issue 1, 2015, Pages 45-52

  Jin, Yan ^a   Sun, Ping Li ^a   Kim, Hyojin ^b   Park, Eunhyang ^b   Shim, Hyo Sup ^c   Jheon, Sanghoon ^a   Kim, Kwhanmien ^a   Lee, Choon Taek ^a   Chung, Jin Haeng ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

FISH; Non small cell lung cancer; Prognosis; ROS1

Indexed keywords

K RAS PROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ONCOPROTEIN; ROS1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER SURVIVAL; CENTROMERE; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROS1 GENE; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CASE REPORT; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84925537844     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-015-1775-y     Document Type: Erratum

References (32)

1. Cardarella S, Johnson BE (2013) The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 188 (7): 770-775. doi: 10. 1164/rccm. 201305-0843PP
2. Birchmeier C, Birnbaum D, Waitches G et al (1986) Characterization of an activated human ROS gene. Mol Cell Biol 6 (9): 3109-3116
3. Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (6): 1190-1203. doi: 10. 1016/j. cell. 2007. 11. 025
4. Ou SH, Bartlett CH, Mino-Kenudson M et al (2012) Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 17 (11): 1351-1375. doi: 10. 1634/ theoncologist. 2012-0311
5. Yoshida A, Kohno T, Tsuta K et al (2013) ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 37 (4): 554-562. doi: 10. 1097/PAS. 0b013e3182758fe6
6. Robinson DR, Wu YM, Lin SF (2000) The protein tyrosine kinase family of the human genome. Oncogene 19 (49): 5548-5557. doi: 10. 1038/sj. onc. 1203957
7. Shaw AT, Hsu PP, Awad MM et al (2013) Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 13 (11): 772-787. doi: 10. 1038/nrc3612
8. Bergethon K, Shaw AT, Ou SH et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30 (8): 863-870. doi: 10. 1200/JCO. 2011. 35. 6345
9. Go H, Kim DW, Kim D et al (2013) Clinicopathologic analysis of ROS1-rearranged non-small cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol 8 (11): 1445-1450. doi: 10. 1097/ JTO. 0b013e3182a4dd6e
10. Pan Y, Zhang Y, Li Y et al (2014) ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer 84 (2): 121-126. doi: 10. 1016/j. lungcan. 2014. 02. 007
11. Mescam-Mancini L, Lantuejoul S, Moro-Sibilot D et al (2014) On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer 83 (2): 168-173. doi: 10. 1016/j. lungcan. 2013. 11. 019
12. Kim MH, Shim HS, Kang DR et al (2014) Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer 83 (3): 389-395. doi: 10. 1016/j. lungcan. 2014. 01. 003
13. Kim HR, Lim SM, Kim HJ et al (2013) The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 24 (9): 2364-2370. doi: 10. 1093/ annonc/mdt220
14. Yoshida A, Tsuta K, Nakamura H et al (2011) Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35 (8): 1226-1234. doi: 10. 1097/PAS. 0b013e3182233e06
15. Edge SB, Byrd DR, Compton CC et al (2010) AJCC cancer staging manual. NY, New York
16. Travis WD, Brambilla E, Muller-Hermeling HK et al (2004) Pathology and genetics of tumours of the lung, Pleura. IARC Press, Lyon, Thymus and Heart. World Health Organization Classification of Tumours
17. Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer/American thoracic society/ European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6 (2): 244-285. doi: 10. 1097/JTO. 0b013e318206a221
18. Seo AN, Yang JM, Kim H et al (2014) Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Br J Cancer 110 (11): 2688-2699. doi: 10. 1038/bjc. 2014. 218
19. Cappuzzo F, Hirsch FR, Rossi E et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97 (9): 643-655. doi: 10. 1093/jnci/ dji112
20. Yoshida A, Tsuta K, Wakai S et al (2014) Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol 27 (5): 711-720. doi: 10. 1038/modpathol. 2013. 192
21. Kim H, Yoo SB, Choe JY et al (2011) Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 6 (8): 1359-1366. doi: 10. 1097/JTO. 0b013e31821cfc73
22. Kim H, Jang SJ, Chung DH et al (2013) A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype. PLoS One 8 (10): e76999. doi: 10. 1371/journal. pone. 0076999
23. Warth A, Muley T, Dienemann H et al (2014) ROS1 expression and translocations in non-small cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology. doi: 10. 1111/his. 12379
24. Ha SY, Roh MS (2013) The new 2011 international association for the study of lung cancer/American thoracic society/European respiratory society classification of lung adenocarcinoma in resected specimens: clinicopathologic relevance and emerging issues. Korean J Pathol 47 (4): 316-325. doi: 10. 4132/KoreanJPathol. 2013. 47.4. 316
25. Takeuchi K, Soda M, Togashi Y et al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18 (3): 378-381. doi: 10. 1038/nm. 2658
26. Inamura K, Takeuchi K, Togashi Y et al (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22 (4): 508-515. doi: 10. 1038/modpathol. 2009. 2
27. Mackinnon AC Jr, Luevano A, de Araujo LC et al (2014) Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma. Mod Pathol. doi: 10. 1038/ modpathol. 2013. 227
28. Salido M, Pijuan L, Martinez-Aviles L et al (2011) Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 6 (1): 21-27. doi: 10. 1097/JTO. 0b013e3181fb7cd6
29. Khadija K, Auger N, Lueza B et al (2012) ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report. J Clin Oncol 30: 2012 (suppl; abstr 10556) 30 (15)
30. Camidge DR, Skokan M, Kiatsimkul P et al (2013) Native and rearranged ALK copy number and rearranged cell count in nonsmall cell lung cancer: implications for ALK inhibitor therapy. Cancer 119 (22): 3968-3975. doi: 10. 1002/cncr. 28311
31. Rimkunas VM, Crosby KE, Li D et al (2012) Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18 (16): 4449-4457. doi: 10. 1158/1078-0432. CCR-11-3351
32. Lee HJ, Seol HS, Kim JY et al (2013) ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Ann Surg Oncol 20 (1): 200-208. doi: 10. 1245/s10434-012-2553-6